

Oncology Today with Dr Neil Love: New Targets in Non-Small Cell Lung Cancer (Interview Audio)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following statements is FALSE about capmatinib for patients with metastatic non-small cell lung cancer (NSCLC)?
 - a. It is FDA approved for patients with MET exon 14 skipping mutations
 - b. It has not demonstrated good CNS penetration
 - c. It has been associated with edema
2. Which of the following agents would NOT be suitable for patients with NSCLC and EGFR exon 20 mutations?
 - a. Poziotinib
 - b. Mobocertinib (TAK-788)
 - c. Selpercatinib
3. Tepotinib has recently received FDA approval for patients with metastatic NSCLC with which of the following genomic alterations?
 - a. EGFR mutations
 - b. RET fusions
 - c. MET exon 14 skipping mutations
4. The antibody-drug conjugate trastuzumab deruxtecan has been associated with which of the following unique side effects in patients with NSCLC and HER2 alterations?
 - a. Central serous retinopathy
 - b. QT interval prolongation
 - c. Interstitial lung disease